Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man
- PMID: 6165740
- PMCID: PMC493291
- DOI: 10.1136/jcp.34.4.361
Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man
Abstract
Rates of urinary excretion concomitant with the molecular size distribution of filtered polymer fragments were determined in five normovolaemic men dosed with 30 g/m2 BSA of a species of HES (HES 350/0.60) possessing a M-W of 350 000 combined with an MS of 0.60. Approximately 13% of the total injected dose of HES 350/0.60 was excreted in urine 1 hr after dosing, and 45% by 72 hours. Gel filtration of Sepharose CL-4B revealed that aliquots of urine collected 1 hour after injection contained polymer fragments of HES 350/0.60 with values of Kav ranging between 0.88 and 0.84, and possessed a Stokes radius (r = 32A) similar to that of Dextran 20 (M-W 22 700). Polymer fragments of HES 350/0.60 excreted 6 to 48 hours after dosing, however, possessed a Kav ranging between 0.78 and 0.73 with a Stokes radius (r = 45A) similar to that of Dextran 40 (M-W 41 000). All filtered polymer fragments were less polydisperse relative to both the injection solution (Kav 0.60) and residual material recovered from blood immediately after injection (Kav 0.72). These data support the hypothesis that the excretion of HES 350/0.60 occurs in two distinct phases: a rapid phase of elimination dependent on the M-n of the injected solution, and a slower phase dependent on the MS (degree of resistance to alpha-amylase attack). This study, in conjunction with our previous investigation of the changes in circulating HES 350/0.60, define the basic differences between clearance and excretion of the dextrans and of the rapidly degraded species of HES. These data are relevant to the utilisation of HES 350/0.60 during centrifugal leucapheresis.
Similar articles
-
Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.J Clin Pathol. 1980 Sep;33(9):880-4. doi: 10.1136/jcp.33.9.880. J Clin Pathol. 1980. PMID: 6159372 Free PMC article.
-
Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.J Clin Pathol. 1980 Feb;33(2):155-9. doi: 10.1136/jcp.33.2.155. J Clin Pathol. 1980. PMID: 6154064 Free PMC article.
-
Changes in the molecular composition of circulating hydroxyethyl starch following consecutive daily infusions in man.Br J Clin Pharmacol. 1979 May;7(5):505-9. doi: 10.1111/j.1365-2125.1979.tb00994.x. Br J Clin Pharmacol. 1979. PMID: 89855 Free PMC article.
-
Clinical pharmacokinetic considerations in the use of plasma expanders.Clin Pharmacokinet. 1987 Feb;12(2):123-35. doi: 10.2165/00003088-198712020-00003. Clin Pharmacokinet. 1987. PMID: 2435442 Review.
-
[Volume replacement with hydroxyethyl starch: is there an influence on kidney function?].Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Feb;39(2):71-7. doi: 10.1055/s-2004-817674. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004. PMID: 14767795 Review. German.
Cited by
-
Investigation of urinary excretion of hydroxyethyl starch and dextran by uhplc-hrms in different acquisition modes.Biol Sport. 2014 Jun;31(2):95-104. doi: 10.5604/20831862.1096045. Epub 2014 Apr 5. Biol Sport. 2014. PMID: 24899772 Free PMC article.
-
Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.Clin Pharmacokinet. 2012 Apr 1;51(4):225-36. doi: 10.2165/11594700-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22420578 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources